Scinai Immunotherapeutics (SCNI) Equity Average (2020 - 2023)

Scinai Immunotherapeutics has disclosed Equity Average across 4 years of filings, most recently posting -$3.3 million for Q1 2023.

• Equity Average for Q1 2023 came in at -$3.3 million, down 5575.0% year-over-year; the trailing twelve-month figure through Mar 2023 was -$3.3 million (down 5575.0% YoY), and the FY2025 annual result was $9.0 million, up 234.32% from the prior year.
• Equity Average came in at -$3.3 million for Q1 2023 at Scinai Immunotherapeutics, down from $372.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $372.7 million in Q4 2022 to a low of -$9.2 million in Q3 2020.
• The 4-year median for Equity Average is -$1.6 million (2022), against an average of $58.9 million.
• Across the five-year window, Equity Average soared 32621.38% in 2022 and tumbled 5575.0% in 2023, its largest moves.
• Scinai Immunotherapeutics' Equity Average stood at -$7.8 million in 2020, then jumped by 114.63% to $1.1 million in 2021, then jumped by 32621.38% to $372.7 million in 2022, then plunged by 100.88% to -$3.3 million in 2023.
• The last three Equity Average figures came in at -$3.3 million (Q1 2023), $372.7 million (Q4 2022), and $60000.0 (Q1 2022), per Business Quant data.